Retatrutide: what it is and what the evidence says
An investigational triple agonist that activates the GIP, GLP-1, and glucagon receptors, studied for its relationship with metabolic regulation and body composition. The glucagon component adds energy expenditure and a marked effect on liver fat.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Metabolism is not a single lever. Talk about metabolic compounds usually collapses three separate mechanisms into one word. Appetite regulation is one. How well cells respond to insulin is another, and largely independent of the first. Mobilizing stored fat is a third. A compound may act on one and leave the other two untouched, so knowing which one is the difference between understanding a molecule and reciting its name.
What it is studied for
Metabolic regulation, definition.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
There are randomized phase 2 trials in obesity, type 2 diabetes, and fatty liver (2023-2024) and a body composition substudy (2025). In phase 3, topline results have been reported for TRIUMPH-4, TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3 in obesity, with mean weight loss of up to 28% at week 80, and TRANSCEND-T2D-1 in type 2 diabetes was published (The Lancet, 2026).
The limitation that matters most
Several phase 3 results are, for now, manufacturer announcements awaiting full publication. Still missing are the cardiovascular and renal outcome trials, long-term safety, a head-to-head comparison with other drugs in its family, and maintenance data after stopping it.
Regulatory status
Not approved in any country as of October 2026; in phase 3. The manufacturer has said it plans to file with the FDA in the first quarter of 2027, and the FDA has stated that it cannot be used in compounding in the United States. It is not listed by name on the 2026 WADA list; anyone who competes under anti-doping rules should confirm its status with their federation.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
It raises resting heart rate and pairs one signal that raises glucose with two that lower it, so pulse, glucose, and lean mass are monitored. It remains in phase 3 and is not yet approved.
Its management belongs to a physician from before the start, especially with arrhythmias, heart disease, diabetes under treatment, or a history of pancreatitis.
What this page cannot give you
A reference page can take you this far. You know what Retatrutide is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a Certificate of Completion with a verifiable certificate ID, a Progress Tracker to follow how you are doing, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trialhuman N Engl J Med · 2023 · PMID 37366315 →
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USAhuman Lancet · 2023 · PMID 37385280 →
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trialhuman Nat Med · 2024 · PMID 38858523 →
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trialhuman Lancet Diabetes Endocrinol · 2025 · PMID 40609566 →
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trialhuman Lancet · 2026 · PMID 42250575 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Retatrutide or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Retatrutide?
An investigational triple agonist that activates the GIP, GLP-1, and glucagon receptors, studied for its relationship with metabolic regulation and body composition. The glucagon component adds energy expenditure and a marked effect on liver fat. It is studied within the area of metabolic.
Is there human evidence for Retatrutide?
There are randomized phase 2 trials in obesity, type 2 diabetes, and fatty liver (2023-2024) and a body composition substudy (2025). In phase 3, topline results have been reported for TRIUMPH-4, TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3 in obesity, with mean weight loss of up to 28% at week 80, and TRANSCEND-T2D-1 in type 2 diabetes was published (The Lancet, 2026).
Is it approved by any health agency?
Not approved in any country as of October 2026; in phase 3. The manufacturer has said it plans to file with the FDA in the first quarter of 2027, and the FDA has stated that it cannot be used in compounding in the United States. It is not listed by name on the 2026 WADA list; anyone who competes under anti-doping rules should confirm its status with their federation.
What is the dose of Retatrutide?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Retatrutide is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.